TY  - GEN 
AU  - Berenbaum, Francis
AU  - BLANCO GARCIA, FRANCISCO JAVIER
AU  - Guermazi, Ali
AU  - Miki, Kenji
AU  - Yamabe, Takaharu
AU  - Viktrup, Lars
AU  - Junor, Rod
AU  - Carey, William
AU  - Brown, Mark T
AU  - West, Christine R
AU  - Verburg, Kenneth M
PY  - 2020
SN  - 0003-4967
UR  - http://hdl.handle.net/20.500.11940/16147
AB  - OBJECTIVE: Tanezumab, a nerve growth factor inhibitor, was investigated for osteoarthritis (OA) of the hip or knee in a study with 24-week treatment and 24-week safety follow-up. METHODS: This double-blind, randomised, phase III study enrolled adults...
LA  - en
KW  - Injections
KW  - Adult
KW  - Middle Aged
KW  - Follow-Up Studies
KW  - Pain Measurement
KW  - Paresthesia
KW  - Osteoarthritis
KW  - Arthroplasty
KW  - Double-Blind Method
KW  - Antibodies
KW  - Humans
KW  - Analgesics
KW  - Musculoskeletal Pain
KW  - Disease Progression
KW  - Aged
KW  - Hypesthesia
TI  - Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period
DO  - 10.1136/annrheumdis-2019-216296
KW  - CHUAC
KW  - INIBIC
VL  - 79
ER  -